Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeuroOne Medical Technologies's revenue for the
three
months ended in Mar. 2026 was $1.86 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $9.19 Mil.
NeuroOne Medical Technologies's Revenue per Share for the
three
months ended in Mar. 2026 was $0.22.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $1.10.
Warning Sign:
NeuroOne Medical Technologies Corp revenue per share is in decline over the past 12 months.
During the past 13 years, NeuroOne Medical Technologies's highest 3-Year average Revenue per Share Growth Rate was 177.00% per year. The lowest was -40.50% per year. And the median was 0.00% per year.
NeuroOne Medical Technologies (NAS:NMTC) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
NeuroOne Medical Technologies Revenue Related Terms
NeuroOne Medical Technologies Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NeuroOne Medical Technologies's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroOne Medical Technologies Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's Revenue distribution charts can be found below:
* The bar in red indicates where NeuroOne Medical Technologies's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.19 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NeuroOne Medical Technologies (NMTC) has a Revenue of $9.19 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on NeuroOne Medical Technologies and its competitors.
Is NeuroOne Medical Technologies' Revenue too high?
NeuroOne Medical Technologies' current Revenue is $9.19 Mil. Overall, NeuroOne Medical Technologies has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' Revenue compare to RDGL and TANAF?
NeuroOne Medical Technologies' Revenue of $9.19 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on NeuroOne Medical Technologies and its competitors. NeuroOne Medical Technologies's current Revenue is $9.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
NeuroOne Medical Technologies (NMTC) has a current Revenue of $9.19 Mil. The current Revenue is $9.19 Mil. NeuroOne Medical Technologies' overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current Revenue is $9.19 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NeuroOne Medical Technologies Business Description
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
21GF Score
Get the complete analysis for NMTC
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NMTC has been successfully added to your 
